(Circulation. 2001;103:1949.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant
The Limone sul Garda Study
From the Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, Milan, Italy (C.R.S., L.C., G.F., D.B., M.A.); Esperion Therapeutics Inc, Ann Arbor, Mich (J.J.); and Cattedra di Semeiotica e Metodologia Medica, University of Brescia, Brescia, Italy (M.S., C.M., R.Z., M.L.M., E.A.).
Correspondence to Professor Cesare Sirtori, Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133 Milano, Italy. E-mail cesare.sirtori{at}unimi.it
Background—Carriers of the apolipoprotein A-IMilano (apoA-IM) mutant present with very low plasma HDL cholesterol and moderate hypertriglyceridemia, apparently not leading to premature coronary heart disease. The objective of this study was to establish whether this high-risk lipid/lipoprotein profile is associated with structural changes in the carotid arteries and heart, indicative of preclinical atherosclerosis.
Methods and Results—Twenty-one A-IM carriers were compared with age- and sex-matched control subjects from the same kindred and with 2 series of matched subjects with primary hypoalphalipoproteinemia (HA). Structural changes in the carotid arteries were defined as the intima-media thickness (IMT) measured by B-mode ultrasound. HA subjects, both recruited among patients attending our Lipid Clinic and blood donors, showed significant thickening of the carotids (average IMT, 0.86±0.25 and 0.88±0.29 mm, respectively) compared with control subjects (average IMT, 0.64±0.12 mm); the apoA-IM carriers instead showed normal arterial thickness (average IMT, 0.63±0.10 mm). Moreover, a significantly higher prevalence of atherosclerotic plaques was found in patients and blood donors with HA (both 57%) compared with apoA-IM carriers (33%) and control subjects (21%). Echocardiographic findings and maximal treadmill ECG did not differ significantly between apoA-IM carriers and control subjects, apart from a slight increase in left ventricular end-diastolic dimension in the carriers.
Conclusions—Despite severe HA, carriers of the apoA-IM mutant do not show structural changes in the arteries and heart, in contrast to HA subjects, who are characterized by a marked increase in carotid IMT and increased prevalence of atherosclerotic plaques.
Key Words: lipoproteins • apolipoproteins • carotid arteries • intima-media thickening • heart diseases
This article has been cited by other articles:
 |
|
 |
|
  E. T. Alexander, G. L. Weibel, M. R. Joshi, C. Vedhachalam, M. de la Llera-Moya, G. H. Rothblat, M. C. Phillips, and D. J. Rader Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I Milano Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1496 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Calabresi, D. Baldassarre, S. Castelnuovo, P. Conca, L. Bocchi, C. Candini, B. Frigerio, M. Amato, C. R. Sirtori, P. Alessandrini, et al. Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans Circulation, August 18, 2009; 120(7): 628 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Alexander, M. Tanaka, M. Kono, H. Saito, D. J. Rader, and M. C. Phillips Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I J. Lipid Res., July 1, 2009; 50(7): 1409 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Grunfeld and K. R. Feingold HDL and innate immunity: a tale of two apolipoproteins J. Lipid Res., August 1, 2008; 49(8): 1605 - 1606. [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Q. Zhao and B. G. Brown ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1110 - 1111. [Full Text] [PDF]
|
|
|
|
|
|
J. Genest The Yin and Yang of high-density lipoprotein cholesterol. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 643 - 644. [Full Text] [PDF]
|
|
|
|
|
|
M. Gomaraschi, D. Baldassarre, M. Amato, S. Eligini, P. Conca, C. R. Sirtori, G. Franceschini, and L. Calabresi Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-IMilano Mutant Circulation, November 6, 2007; 116(19): 2165 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Weibel, E. T. Alexander, M. R. Joshi, D. J. Rader, S. Lund-Katz, M. C. Phillips, and G. H. Rothblat Wild-Type ApoA-I and the Milano Variant Have Similar Abilities to Stimulate Cellular Lipid Mobilization and Efflux Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2022 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garg and V. Simha Update on Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1581 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Drexel Reducing risk by raising HDL-cholesterol: the evidence Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F23 - F29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Berglund Lipoprotein Metabolism: A Well-Tried Tool to Characterize Dyslipidemic Mechanisms. Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1201 - 1203. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow High-Density Lipoprotein Function: Recent Advances J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1792 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F15 - F22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhu, G. Wu, W. Zeng, H. Xue, and B. Chen Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties J. Lipid Res., June 1, 2005; 46(6): 1303 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Futterman and L. Lemberg Apo A-I Milano Am. J. Crit. Care., May 1, 2005; 14(3): 244 - 247. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marchesi, E. A. Booth, T. Davis, C. L. Bisgaier, and B. R. Lucchesi Apolipoprotein A-IMilano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1023 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hovingh, A. Brownlie, R. J. Bisoendial, M. P. Dube, J. H.M. Levels, W. Petersen, R. P.F. Dullaart, E. S.G. Stroes, A. H. Zwinderman, E. de Groot, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1429 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne and V. Nambi Apolipoprotein A-I and high-density lipoprotein: Is this the beginning of the era of noninvasive angioplasty? J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1436 - 1438. [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, B. Coin, A. Hedayiti, J. Yano, B. Cercek, K.-Y. Chyu, and P. K. Shah Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-IMilano-phospholipid complex J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Manolio, E. Boerwinkle, C. J. O'Donnell, and A. F. Wilson Genetics of Ultrasonographic Carotid Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1567 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhat, M. Zabalawi, M. C. Willingham, G. S. Shelness, M. J. Thomas, and M. G. Sorci-Thomas Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions J. Lipid Res., July 1, 2004; 45(7): 1207 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial JAMA, November 5, 2003; 290(17): 2292 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parolini, G. Chiesa, Y. Zhu, T. Forte, S. Caligari, E. Gianazza, M. G. Sacco, C. R. Sirtori, and E. M. Rubin Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION J. Biol. Chem., February 7, 2003; 278(7): 4740 - 4746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Hong, W. Riley, J. Rhyne, G. Friel, and M. Miller Lack of Association between Increased Carotid Intima-Media Thickening and Decreased HDL-Cholesterol in a Family with a Novel ABCA1 Variant, G2265T Clin. Chem., November 1, 2002; 48(11): 2066 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baldassarre, M. Amato, L. Pustina, E. Tremoli, C. R. Sirtori, L. Calabresi, and G. Franceschini Increased Carotid Artery Intima-Media Thickness in Subjects With Primary Hypoalphalipoproteinemia Arterioscler Thromb Vasc Biol, February 1, 2002; 22(2): 317 - 322. [Abstract] [Full Text] [PDF]
|
|